Aligos Therapeutics (ALGS) Cash & Current Investments (2019 - 2026)

Aligos Therapeutics has reported Cash & Current Investments for 8 years, with the latest figure at $79.8 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Current Investments fell 42.16% year-over-year to $79.8 million; the trailing twelve-month figure through Mar 2026 stood at $79.8 million (down 42.16% YoY), and the FY2025 full-year result was $77.8 million, up 36.71% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $79.8 million, up from $77.8 million in the prior quarter.
• The five-year high for Cash & Current Investments was $201.3 million in Q1 2024, with the low at $18.8 million in Q2 2025.
• Historically, Cash & Current Investments has averaged $103.8 million across 5 years, with a median of $90.8 million in 2023.
• Annual changes were most pronounced in 2024 — Cash & Current Investments surged 154.58% — and 2025, when it plunged 80.15%.
• Aligos Therapeutics' Cash & Current Investments stood at $81.5 million in 2022, then soared by 66.71% to $135.8 million in 2023, then slumped by 58.07% to $56.9 million in 2024, then soared by 36.71% to $77.8 million in 2025, then grew by 2.55% to $79.8 million in 2026.
• The last three Cash & Current Investments figures came in at $79.8 million (Q1 2026), $77.8 million (Q4 2025), and $156.2 million (Q3 2025), per Business Quant data.